There are several shares in the S&P/ASX 200 Index (ASX: XJO) that I think could have a particularly strong 2027.
Some have exciting growth opportunities, while others are working through challenges that could eventually leave them in a much better position.
Here are three I think could outperform the broader market next year.
Image source: Getty Images
WiseTech Global Ltd (ASX: WTC)
WiseTech is a technology company I think could surprise investors in 2027.
The logistics software provider has endured a difficult period, with governance concerns, acquisition-related challenges, and questions about its growth outlook weighing on investor confidence.
But I think there are reasons to be more optimistic. Its CargoWise platform has become an important part of how major freight forwarders manage international shipments.
What interests me is that several large customers have already committed to implementing the software across their operations. As those deployments progress, WiseTech has an opportunity to generate more revenue from customers it has already secured.
The company is also working to improve profitability through cost reductions and the integration of e2open.
Management expects underlying EBITDA growth of between 12% and 21% in FY27, with margins improving as its efficiency initiatives deliver results.
There is plenty of execution risk, particularly around customer adoption of new products and pricing models. But I think a return to stronger earnings growth could help rebuild confidence in WiseTech shares.
Sigma Healthcare Ltd (ASX: SIG)
Sigma is another ASX 200 share I believe could deliver impressive returns in 2027.
Following its merger with Chemist Warehouse, the company has become a major force in Australian pharmacy retailing and pharmaceutical distribution.
What I like is the opportunity to keep growing its business even when households are watching their spending.
Consumers still need prescription medicines and everyday healthcare products, while Chemist Warehouse's discount offering gives shoppers a reason to visit.
And its latest trading update suggests that strategy is working. Australian Chemist Warehouse stores recorded sales growth of 12.1% in the financial year to date, while international sales increased 30.2%.
I also like that Sigma is expanding its store network while working towards $100 million in annual merger synergies by FY29. That creates opportunities to improve earnings through both additional sales and greater efficiency.
Because of this, I think Sigma has plenty of momentum heading into 2027.
Treasury Wine Estates Ltd (ASX: TWE)
My final pick is more of a recovery opportunity. Treasury Wine Estates has experienced a challenging period, particularly in China and the United States.
Weaker demand, distribution difficulties, and excess inventory have put considerable pressure on its financial performance.
But I think there are reasons to believe 2027 could mark an important turning point for the ASX 200 share. The company is simplifying its operations and concentrating investment on its strongest wine brands, including Penfolds.
Encouragingly, management recently reported that Penfolds sales to consumers in China were performing slightly ahead of expectations.
Treasury Wine Estates is also making progress on reducing excess inventory and implementing its transformation programme, which is targeting $100 million in annual cost savings by FY29.
Management expects FY27 operating earnings to be at least in line with FY26, so a substantial earnings recovery may take longer.
But if investors begin seeing evidence that the turnaround is working, I think Treasury Wine Estates shares could recover well before earnings reach their full potential.
Foolish takeaway
I think all three shares have the potential to outperform the ASX 200 in 2027.
WiseTech and Sigma have opportunities to build on their existing businesses, while Treasury Wine Estates could benefit from improving investor confidence as its recovery progresses.
None is guaranteed to beat the market, but I would be happy buying these shares today and giving their investment cases time to play out.
